Worrall Graham
Memorial University of Newfoundland, Newfoundland, Canada.
BMJ Clin Evid. 2006 Oct 1;2006:1704.
Herpes simplex virus type 1 infection usually causes a mild, self-limiting painful blistering around the mouth, with 20-40% of adults affected at some time. Primary infection usually occurs in childhood, after which the virus is thought to remain latent in the trigeminal ganglion. Recurrence may be triggered by factors such as exposure to bright light, stress, and fatigue.
We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of antiviral treatments for the first attack of herpes labialis? What are the effects of interventions aimed at preventing recurrent attacks of herpes labialis? What are the effects of treatments for recurrent attacks of herpes labialis? We searched: Medline, Embase, The Cochrane Library and other important databases up to April 2006 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
We found 25 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
In this systematic review we present information relating to the effectiveness and safety of the following interventions: oral antiviral agents (acyclovir, and valaciclovir), sunscreen, topical anaesthetic agents, topical antiviral agents (acyclovir, and penciclovir), and zinc oxide cream.
1型单纯疱疹病毒感染通常会在口腔周围引起轻度、自限性的疼痛性水疱,约20% - 40%的成年人在某些时候会受到影响。初次感染通常发生在儿童期,之后病毒被认为潜伏在三叉神经节中。复发可能由暴露于强光、压力和疲劳等因素触发。
我们进行了一项系统评价,旨在回答以下临床问题:抗病毒治疗对唇疱疹首次发作有何影响?旨在预防唇疱疹复发的干预措施有何影响?治疗唇疱疹复发的措施有何影响?我们检索了:截至2006年4月的Medline、Embase、Cochrane图书馆及其他重要数据库(临床证据综述会定期更新,请查看我们的网站获取本综述的最新版本)。我们纳入了来自美国食品药品监督管理局(FDA)和英国药品及医疗产品监管局(MHRA)等相关组织的危害警示。
我们发现了25项符合我们纳入标准的系统评价、随机对照试验或观察性研究。我们对干预措施的证据质量进行了GRADE评估。
在本系统评价中,我们提供了以下干预措施有效性和安全性的相关信息:口服抗病毒药物(阿昔洛韦和伐昔洛韦)、防晒霜、局部麻醉剂、局部抗病毒药物(阿昔洛韦和喷昔洛韦)以及氧化锌乳膏。